Bioavailable iron supplement containing a ferric hydroxide core stabilized and solubilized by simple carbohydrates. Prepn: W. Traube et al., Ber. 66B, 1545 (1933). Intestinal absorption of clinical formulations: L. Samochowiec, Clin. Ter. 56, 341 (1971).
Aqueous iron formulation administered as an injectable, stable, macromolecular iron saccharate complex. Gluconate bridges the iron centers. Mol formula is approximately: [NaFe2O3(C6H11O7)(C12H22O11)5]n. Apparent mol wt 289-440 kDa. Safety profile: G. Faich, J. Strobos, Am. J. Kidney Dis. 33, 464 (1999). Clinical evaluation in hemodialysis patients: A. R. Nissenson et al., ibid. 471; and comparison with iron dextran: B. Michael et al., Kidney Int. 61, 1830 (2002). Clinical pharmacokinetics: P. A. Seligman et al., Pharmacotherapy 24, 574 (2004). Clinical evaluation in renal transplant patients: R. S. Gillespie, J. M. Symons, Pediatr. Transplant. 9, 43 (2005). Review of therapeutic applications: S. Fishbane, J. Wagner, Am. J. Kidney Dis. 37, 879-883 (2001).
Hematinic.
Hematinic